Oxbryta

The Oxbryta lawsuit represents a growing legal response to complications linked to the sickle cell medication Oxbryta, also known as voxelotor. Plaintiffs allege that Oxbryta, originally developed by Global Blood Therapeutics and later acquired by Pfizer, caused serious side effects such as blood-related complications, organ damage, and in some cases, patient death—raising questions about the drug’s long-term safety.

Legal scrutiny intensified following reports of adverse events and growing concern from medical professionals about insufficient risk disclosure. Although no formal FDA recall has been issued to date, mounting litigation points to alleged failures in post-market safety monitoring, manufacturing accountability, and informed consent practices.